The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.
This approval expands the indication for idecabtagene vicleucel (Abecma) to include patients who have relapsed or become refractory to a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody after at least two prior lines of therapy.
“Abecma has demonstrated a progression-free survival benefit three times that of standard regimens in relapsed or refractory
